Compare LWLG & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWLG | DBVT |
|---|---|---|
| Founded | 1991 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.9M | 692.2M |
| IPO Year | 2011 | 2014 |
| Metric | LWLG | DBVT |
|---|---|---|
| Price | $3.01 | $9.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $36.51 |
| AVG Volume (30 Days) | ★ 3.6M | 293.9K |
| Earning Date | 11-10-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.79 | 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | $236,855.00 | ★ $5,636,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $257.14 | $1,837.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 147.74 | 35.77 |
| 52 Week Low | $2.83 | $8.63 |
| 52 Week High | $18.71 | $26.19 |
| Indicator | LWLG | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 41.29 |
| Support Level | N/A | $8.78 |
| Resistance Level | $5.73 | $10.86 |
| Average True Range (ATR) | 0.45 | 0.78 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 8.79 | 18.20 |
Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.